Over the past decades, neoadjuvant therapy has become a preferred option in locally advanced, [1] inflammatory, node-positive, triple-negative (TN), or human epidermal growth factor receptor 2 (HER2) – overexpressing, non-metastatic breast cancers (BCs) [2–4]. The gene discussed is ERBB2; the disease is breast carcinoma.